JSH-23: Precision NF-κB Inhibitor for Inflammation Research

Executive Summary: JSH-23 (CAS 749886-87-1) is a synthetic small molecule that selectively inhibits NF-κB transcriptional activity by blocking p65 nuclear localization without affecting IκB degradation (APExBIO). Its IC50 is approximately 7.1 μM in cell-based assays. In LPS-stimulated RAW 264.7 macrophages, JSH-23 reduces pro-inflammatory mediators including IL-6, IL-1β, COX-2, and TNF-α. Intraperitoneal administration in cisplatin-induced acute kidney injury models significantly decreases BUN, serum creatinine, and inflammatory cytokines. JSH-23 is a benchmark research reagent for dissecting NF-κB signaling in inflammation and disease models (Gao et al., 2023).

Biological Rationale

NF-κB is a master transcription factor regulating immune and inflammatory responses. Its dysregulation is implicated in disorders such as inflammatory bowel disease, acute kidney injury, and sepsis (Gao et al., 2023). The canonical pathway involves cytoplasmic retention by IκB, followed by nuclear translocation of the p65/p50 complex upon stimulation. Targeting NF-κB—specifically the p65 subunit—enables focused modulation of pro-inflammatory genes including IL-6, IL-1β, and TNF-α. JSH-23 was developed to provide precise inhibition downstream of IκB degradation, allowing researchers to interrogate nuclear signaling events with minimal off-target effects. Compared to broad-spectrum anti-inflammatories, JSH-23 offers specificity for transcriptional regulation, minimizing disruption to upstream cellular processes.

Mechanism of Action of JSH-23

JSH-23 (4-methyl-1-N-(3-phenylpropyl)benzene-1,2-diamine) is a small molecule that acts by inhibiting the nuclear localization and DNA binding activity of the NF-κB p65 subunit. It does not impact IκB degradation, distinguishing it mechanistically from proteasome inhibitors and upstream kinase blockers. In LPS-stimulated macrophages, JSH-23 blocks the transactivation of NF-κB-dependent genes, resulting in reduced production of IL-6, IL-1β, COX-2, and TNF-α. This mechanism was confirmed by nuclear extraction and DNA binding assays, which showed diminished p65 activity following JSH-23 treatment (APExBIO). The compound is highly soluble in DMSO (≥24 mg/mL) and ethanol (≥17.1 mg/mL with ultrasonication), but insoluble in water. Its molecular weight is 240.34 Da, with a formula of C16H20N2. JSH-23’s unique mode of action allows for dissection of downstream NF-κB transcriptional events without globally suppressing cytoplasmic signaling intermediates.

Evidence & Benchmarks

• JSH-23 inhibits NF-κB transcriptional activity in RAW 264.7 macrophages with an IC50 of ~7.1 μM (APExBIO).
• Reduces nuclear localization and DNA binding of NF-κB p65, confirmed by EMSA and immunoblotting (APExBIO).
• Suppresses LPS-induced expression of IL-6, IL-1β, COX-2, and TNF-α in cell culture models (Gao et al., 2023).
• Intraperitoneal JSH-23 in cisplatin-induced acute kidney injury models lowers BUN, creatinine, NGAL, and cytokine levels in male C57BL/6 mice (8–10 weeks, 20–25g) (APExBIO).
• Does not block IκB degradation, as shown by western blot in cell lysates post-LPS stimulation (Interlink: JSH-23: Precision NF-κB Inhibitor).
• Demonstrated selectivity for the NF-κB pathway over other inflammation mediators, such as the NLRP3 inflammasome (Gao et al., 2023).

Applications, Limits & Misconceptions

JSH-23 is widely used as a research tool in inflammation and immunology. Its applications include:

• Dissecting NF-κB-dependent gene regulation in primary and immortalized cell lines.
• Modeling cytokine and chemokine suppression in animal models of acute and chronic inflammation.
• Screening for anti-inflammatory activity in drug discovery pipelines.
• Serving as a benchmark for comparison with natural products or biologics targeting the NF-κB pathway (Gao et al., 2023).

Compared with JSH-23: Precise NF-κB Inhibition for Inflammation Research, which details foundational workflow integration, this article provides expanded quantitative benchmarks and clarifies application limits in vivo.

Common Pitfalls or Misconceptions

• JSH-23 does not inhibit upstream kinases or proteasome activity—it specifically blocks p65 nuclear localization.
• It is not effective in models where inflammation is NF-κB-independent (e.g., NLRP3-driven colitis without p65 involvement).
• The compound is insoluble in water; improper solvent use can lead to experimental failure.
• Long-term storage of JSH-23 solutions is not recommended; use freshly prepared stocks for reproducibility.
• JSH-23 should not be interpreted as a clinical therapeutic—it is a research-use-only molecule.

Workflow Integration & Parameters

For cell-based experiments, JSH-23 is typically dissolved in DMSO and applied at final concentrations between 5–20 μM, depending on cell type and readout. Vehicle controls are essential to distinguish compound-specific effects from solvent artifacts. In animal studies, intraperitoneal administration is performed using freshly prepared solutions; doses and schedules are tailored to model requirements, as described for cisplatin-induced acute kidney injury (single or multiple injections, 20–50 mg/kg) (APExBIO). APExBIO recommends storage at -20°C and cautions against prolonged solution storage for assay reproducibility.

To extend the discussion from JSH-23: Advanced Insights into NF-κB Inhibition and Inflammation, which focuses on mechanistic perspectives, this article details stepwise experimental integration and highlights best practices for maximizing data quality.

Conclusion & Outlook

JSH-23, supplied by APExBIO, is a robust and selective inhibitor of NF-κB p65 nuclear translocation, validated across cell and animal models of inflammation. Its specificity enables precise interrogation of transcriptional events in the NF-κB signaling pathway. While highly effective in NF-κB-driven contexts, JSH-23 is not a universal anti-inflammatory and should be applied with awareness of pathway dependencies. As research advances, JSH-23 remains a key benchmark tool for dissecting NF-κB function and informing the development of targeted anti-inflammatory strategies.

For detailed product specifications, protocols, and ordering information, see the JSH-23 product page (B1645).

For further reading on translational applications and future research directions, see JSH-23 and the Future of Translational Inflammation Research, which complements this article by exploring forward-looking perspectives and clinical translation potential.